Biotech Values

[mcbio]

Potential negative sentiment today for ISIS and ALNY, but suggests their drugs could find success with this target too.

I view this as positive for ISIS and ALNY insofar as it provides further validation for PCSK9 as a target, this is an extremely large market opportunity so there is room for several players, and as noted in follow-on posts, the ISIS and ALNY drugs could potentially be able to differentiate themselves from the SNY/REGN drug.